Delta Sleep
Delta sleep-inducing peptide (DSIP) — investigational neuromodulatory peptide · Pre-filled pen
Delta Sleep (delta sleep-inducing peptide, DSIP) is a naturally occurring nonapeptide whose mechanism is not fully characterised. It has been associated in research with modulation of neurotransmitter systems relevant to slow-wave (delta) sleep onset and maintenance, and with neuroendocrine and circadian signalling that may influence the stress response. The evidence base in humans is very limited and largely exploratory.
Studied use areas
- Studied for slow-wave (delta) sleep architecture and sleep-depth markers
- Explored for sleep onset and maintenance endpoints
- Investigated at the sleep–stress interface where stress load impairs rest
- Examined for next-day recovery and readiness markers
- Discussed in neuroendocrine and circadian-rhythm research contexts
Safety & status
- Investigational peptide with very limited human data; not an approved medicine.
- Efficacy, long-term safety, and interactions are not established.
- Any use must be assessed and supervised by a qualified physician.
⚕ Clinical note: This card is educational and not medical advice. Delta Sleep (DSIP) is investigational with only limited human evidence, is not a licensed treatment for insomnia or any sleep or stress disorder, and no benefit is guaranteed; any use must be individualised and determined by a treating physician.
Evidence: Very limited human evidence (investigational) — GRADE D · References: Peer-reviewed sleep-neuroscience and neuropeptide research literature; Exploratory human and preclinical studies on delta sleep-inducing peptide (DSIP); EMA/MHRA regulatory guidance on investigational compounds
